PHAI

Pharmachain AI by Virtuals Price Today & AI Analysis

PHAIBaseAnalysis as of May 2, 2026

Price

$0.059608

+0.00% 24h

Contract

Live
0x3513e4a7d27d18c2c894d98bc5a55406360b9ba3

Chain

Base

Holders

4.3K

Market cap

$9.61K

Liquidity

$6.17K

At a $1M market cap, $PHAI would be $0.001000 (104x from today’s price)

Market cap calculator

Is PHAI a scam?

Unhosted check · Oct 26

Not checked

This contract has not been tested for honeypots or taxes yet.

The honeypot and tax test has not run on this contract yet, so no red flags here does not mean a clean contract. Unhosted’s automated check, re-run in the background: a warning signal, not a guarantee either way. Taxes come from a test trade through one pool and can change if the owner changes them.

Ask Unhosted AI about PHAI

3 free answers a day

What's Twitter saying?Whale activityWhat are the risks?Should I buy?

More tokens on Base

KKNNEXKNNEX$0.071663+0.0%MC $3SSEEDSproutly$0.079156+0.0%MC $91.6KPPANGEAPangea$0.053156+0.0%MC $315.6KGGBGitlawb Intern$0.062591+0.0%MC $25.9KUUSMSUnited States Mineral Supply$0.056689+0.0%MC $668.9KAnthropicAnthropicAnthropic$0.000102+920.2%MC $10.20M

Pharmachain AI by Virtuals: holders, selling & liquidity

2026-05-02 21:01 UTC

Holder addresses

4,124

Top 10 supply share

Not available

Reported liquidity

$49,235.24
How concentrated is Pharmachain AI by Virtuals ownership?
Top-10 ownership concentration is not available in this report. The saved holder count is 4,124 addresses (2026-05-02 21:01 UTC). A holder count alone does not establish how supply is distributed.
Are large holders selling Pharmachain AI by Virtuals?
This report cannot establish whether large holders are selling: it does not include wallet-level holder balances over time matched to swaps. A complete buy/sell volume observation is not available in the saved inputs. A large swap alone does not identify a large holder, and a transfer alone does not prove a sale.
Is Pharmachain AI by Virtuals liquidity falling?
As of 2026-05-02 21:01 UTC, reported liquidity was $49,235.24. At least two timestamped liquidity observations are needed to establish a change; this report does not have them.
Sources, observations & limitations

Source: inputs saved with the report generated 2026-05-02 21:01 UTC. Original provider retrieval times and historical samples were not recorded. Legacy zero placeholders are treated as unavailable. Holder addresses are not unique people. The provider’s top-10 share is not adjusted here for pools, exchanges, burn addresses or related wallets. Sniper classifications and wallet-level holder history are unavailable. Inspect token on the block explorer.

Recent swap evidence

Swap evidence is unavailable for this report.

Loading price chart…

1h chart read; Support, resistance, Fibonacci and RSI divergence are drawn on the chart once it loads.

Ask Wick about this chart

Advanced charting powered by TradingView

Movement since report

report from May 2, 2026, 09:01 PM UTC

Market Cap

$55.71K

24h Volume

$96.55K

Liquidity

$49.24K

FDV

—

Holders

4,124

24h

Loading trading activity…

AI Executive Summary

Risk

Very high

Sentiment

Bearish

Pharmachain AI (PHAI) is an early-stage AI utility token targeting pharmaceutical supply chain optimization through real-time inventory tracking and shortage prediction. The token addresses a genuine $1.65 trillion market problem with documented inefficiencies, but currently shows critical structural weaknesses including extreme holder concentration (100% in top 10), minimal liquidity ($49K), and no verifiable project traction. The recent 263% price surge appears driven by speculative trading rather than fundamental adoption, with concerning distribution patterns suggesting potential pump-and-dump dynamics.

Figures cited above are from the market snapshot taken when this analysis ran — May 2, 2026, 09:01 PM UTC. Live values may differ; the key facts at the top of the page are current.

Key points

  • Targets underserved pharmaceutical supply chain problem with documented FDA shortage crisis
  • Combines AI-driven inventory optimization with shortage prediction capabilities
  • Addresses both developed markets (US: 41K pharmacies, 340M people) and emerging markets (Africa: 4.5K pharmacies, 200M people) with severe distribution gaps

Pharmachain AI by Virtuals AI Price Analysis

Low Confidence

Short-Term · 24h-7d

Bearish

PHAI has experienced explosive 263% gains in 24 hours, indicating a parabolic move that typically precedes sharp corrections. The 55.8% buy pressure is being offset by concerning holder concentration (100% in top 10), suggesting limited organic demand. Short-term price action is likely to consolidate or retrace as early buyers take profits.

Medium-Term · 30d-90d

Neutral

Medium-term outlook depends entirely on project execution and holder distribution normalization. If the team successfully addresses concentration risk and demonstrates real pharmaceutical supply chain integration, the token could stabilize and build. However, without significant fundamental progress and retail adoption, the token faces structural headwinds from its current distribution model.

Bullish Factors

  • Addresses massive $1.65T pharmaceutical market with documented inefficiencies in drug distribution
  • Real problem statement: FDA lists hundreds of essential medicines in shortage while identical drugs expire elsewhere
  • Strong conceptual value proposition: real-time pharmacy inventory + shortage prediction could save billions in losses
  • Buy pressure at 55.8% with 164 buy transactions vs 166 sell transactions shows relatively balanced participation
  • Holder growth of 35 new holders in 24h (0.85%) indicates ongoing interest despite parabolic move
  • Contract verified on-chain, reducing smart contract risk

Bearish Factors

  • Critical concentration risk: Top 10 holders control 100% of supply, top 100 holders control 100% - this is a massive red flag for manipulation and exit liquidity
  • Extremely shallow liquidity at only $49,235 USD - any significant sell pressure will cause severe slippage and price collapse
  • Market cap of only $55,714 with fully diluted valuation of $129,437 suggests minimal real adoption or utility
  • 263% 24-hour gain is unsustainable parabolic move typical of pump-and-dump patterns, not organic growth
  • Security score of 47/100 indicates moderate-to-high smart contract risk despite verification
  • No evidence of actual pharmaceutical partnerships, pilot programs, or real-world implementation
  • Retail holders represent ~0% of supply - 416 octopus holders (<$1K each) own negligible amounts while whales dominate
  • 3,736 holders acquired via transfer (90.5% of acquisition method) rather than organic swaps (6.9%), suggesting airdrop/distribution scheme
  • Only 105 unique buyers in 24h for a token with 4,124 holders indicates low organic trading activity

Disclaimer: This AI-generated prediction is for informational purposes only and does not constitute financial advice. Cryptocurrency investments are highly volatile. Always conduct your own research.

Token Info

Chain
Base
Contract
0x3513...9ba3
Total Supply
—
Decimals
—

Key Risks

  • Critical concentration risk: 100% of supply in top 10 holders creates single point of failure and extreme exit liquidity risk. Any coordinated whale exit would crash price 80%+.
  • Extreme liquidity risk: $49K liquidity is insufficient for meaningful trading. Position sizes above $5-10K will experience severe slippage. This creates a liquidity trap for retail buyers.
  • Parabolic price action: 263% 24h gain is unsustainable and typically precedes 50-80% corrections. The pattern suggests we may be near a local top.
  • Zero project traction: No evidence of pharmaceutical partnerships, pilot programs, or real-world implementation. The token is purely speculative with no fundamental support.

Trading Insight

bearish

Despite positive buy pressure (55.8%), trading sentiment is bearish due to parabolic price action, extreme concentration, and low participation breadth. The 330 total transactions in 24h across 4,124 holders (8% participation rate) indicates most holders are passive, not active traders. This suggests limited organic demand and high vulnerability to coordinated selling.

AI-generated insight. Not financial advice.

Frequently Asked Questions

Trend Analysis

Short-Term (7d)

Bullish

Medium-Term (30d)

Neutral

Short-term trend is strongly upward with 263% 24h gains, but this is a parabolic move characteristic of unsustainable rallies. The 4-hour gain of 205% and 1-hour gain of 32% show acceleration into the move, which typically precedes reversal. Medium-term trend is likely to be sideways consolidation or downtrend as the market reprices after the initial spike.

Momentum

Status

Overbought

Extreme overbought conditions indicated by 263% 24h move with minimal volume ($96.5K total). The 5-minute change of 0% after such explosive moves suggests momentum is exhausting. Overbought conditions typically resolve through either consolidation or sharp correction. The buy pressure of 55.8% is elevated but not extreme, suggesting some sellers are already taking profits.

Volume Analysis

Buy

55.8%

Sell

44.2%

Volume Trend

Increasing

Volume trend shows recent acceleration with 4-hour volume comparable to 24-hour volume, indicating buying pressure is concentrating into recent candles. However, absolute volume of $96.5K in 24h is extremely thin for a token with $55K market cap - this represents only 1.7x market cap in daily volume, which is low. The increasing trend is concerning because it's driving parabolic price action on minimal liquidity, creating extreme slippage risk.

Recent Price Action

Classic parabolic spike pattern: 0% (5min) → 32% (1h) → 205% (4h) → 263% (24h). This shows accelerating gains with each timeframe, which is the hallmark of unsustainable moves. The 5-minute stagnation at 0% after the spike suggests momentum is exhausting at current levels.

Parabolic patterns typically resolve through sharp corrections of 50-80% as early buyers take profits and late buyers panic sell. This pattern is historically associated with high-risk, low-liquidity tokens and often precedes significant drawdowns. The pattern suggests we may be near a local top.

Key Price Levels

Immediate support

$0.00008

Major support

$0.00004

Immediate resistance

$0.00020

Major resistance

$0.00035

Immediate support at $0.00008 represents a 38% pullback from current levels and would likely hold if profit-taking is orderly. Major support at $0.00004 represents a 69% correction and would likely hold if there's no panic selling. Immediate resistance at $0.00020 is a psychological level that could attract sellers. Major resistance at $0.00035 would represent a 170% move from current levels and is unlikely in near term without fundamental catalyst.

AI overall risk

Very high

Risk Score

92/100

Risk Breakdown

  • VolatilityHigh

    263% 24h gain demonstrates extreme volatility. The parabolic price action and thin liquidity create conditions for 50-80% corrections. Volatility is likely to remain extreme until the token either gains real traction or collapses.

  • LiquidityHigh

    Only $49K liquidity is critically shallow. Any position above $5-10K will experience severe slippage. Exit liquidity is severely constrained - large holders cannot exit without crashing price. This creates a liquidity trap where early buyers are locked in.

  • ConcentrationNot assessed

    Ownership concentration cannot be assessed without a measured supply distribution.

  • Smart ContractNot assessed

    Contract or authority checks are not included in the saved provider observations.

  • RegulatoryMedium

    Healthcare-related tokens face regulatory uncertainty. If PHAI claims to provide medical advice or drug shortage predictions, it may face FDA or healthcare regulatory scrutiny. The token's pharmaceutical focus could attract regulatory attention if it gains traction.

Key Risks

  • Critical concentration risk: 100% of supply in top 10 holders creates single point of failure and extreme exit liquidity risk. Any coordinated whale exit would crash price 80%+.
  • Extreme liquidity risk: $49K liquidity is insufficient for meaningful trading. Position sizes above $5-10K will experience severe slippage. This creates a liquidity trap for retail buyers.
  • Parabolic price action: 263% 24h gain is unsustainable and typically precedes 50-80% corrections. The pattern suggests we may be near a local top.
  • Zero project traction: No evidence of pharmaceutical partnerships, pilot programs, or real-world implementation. The token is purely speculative with no fundamental support.
  • Suspicious distribution: 90.5% of holders acquired via transfer (airdrop) rather than organic swaps. Combined with 100% concentration, this suggests potential pump-and-dump structure.
  • Slowing adoption: Holder growth of only 0.85% in 24h despite 263% price gains suggests the token has reached its distribution targets and is not attracting new organic buyers.
  • Regulatory uncertainty: Healthcare-related tokens face potential FDA or healthcare regulatory scrutiny if they claim to provide medical advice or shortage predictions.

Mitigating Factors

  • Real problem statement: The pharmaceutical supply chain inefficiency is documented and genuine, providing potential long-term value if the project can execute
  • Verified contract: The smart contract is verified on-chain, reducing some smart contract risks
  • Uniswap v2 infrastructure: Deployed on battle-tested DEX infrastructure rather than custom AMM
  • Early stage: As an early-stage project, there is potential for significant upside if fundamentals develop

Investor Suitability

PHAI is suitable ONLY for: (1) Experienced cryptocurrency traders with high risk tolerance, (2) Investors who can afford to lose 100% of their investment, (3) Speculators willing to accept extreme volatility and liquidity constraints, (4) Those with conviction in the long-term pharmaceutical supply chain use case and willingness to hold through 80%+ drawdowns. PHAI is NOT suitable for: (1) Conservative investors, (2) Those seeking stable returns, (3) Retail investors with limited trading experience, (4) Anyone who cannot afford to lose their entire investment, (5) Those seeking near-term returns.

Pharmachain AI addresses a genuine $1.65 trillion market problem with documented inefficiencies in pharmaceutical distribution, but currently shows critical structural weaknesses that make it a high-risk speculative asset rather than a sound investment. The token's extreme concentration (100% in top 10 holders), minimal liquidity ($49K), and zero project traction suggest the current price is driven by speculation rather than fundamental value. Success would require the team to demonstrate real pharmaceutical partnerships and user adoption while normalizing holder distribution.

Scenario Analysis

Bull Case

Low probability

Pharmachain AI successfully partners with major pharmacy networks or healthcare providers and demonstrates real-world utility in optimizing drug distribution. The token gains genuine adoption as a utility token for accessing the platform, driving organic demand. Holder concentration normalizes as retail adoption increases. The token captures a meaningful portion of the $1.65 trillion pharmaceutical market opportunity.

  • Successful pharmaceutical partnerships with major chains (CVS, Walgreens, etc.) or healthcare systems
  • Demonstrated reduction in drug expiry losses or improvement in shortage response times
  • Regulatory approval for healthcare supply chain applications
  • Organic retail adoption driving holder normalization
  • Integration with FDA shortage tracking systems

Base Case

PHAI experiences a 50-70% correction from current levels as profit-taking occurs and speculative interest wanes. The token stabilizes at a lower valuation ($15-25K market cap) where it trades based on development progress rather than speculation. The team gradually builds partnerships and demonstrates proof-of-concept, but adoption remains slow due to regulatory barriers and incumbent competition. The token remains a high-risk, low-liquidity asset suitable only for long-term believers in the pharmaceutical supply chain use case.

  • Parabolic price action is unsustainable and will correct 50-70% in near term
  • Project team has genuine commitment to pharmaceutical supply chain optimization
  • Regulatory barriers will slow but not prevent adoption
  • Holder concentration will gradually normalize as project gains traction
  • Token will remain illiquid and volatile for 12-24 months

Bear Case

High probability

The current price is driven by speculative trading and pump-and-dump dynamics rather than fundamental value. Early whales take profits, causing a 70-90% correction. The project fails to demonstrate real traction or partnerships. Holder concentration remains extreme, preventing organic adoption. The token becomes a cautionary tale of speculative excess in crypto markets.

  • Coordinated whale exit causing liquidity crisis and price collapse
  • Failure to announce meaningful pharmaceutical partnerships within 3-6 months
  • Continued extreme holder concentration preventing retail adoption
  • Regulatory scrutiny on healthcare claims without FDA approval
  • Competing solutions from established pharmaceutical companies or better-funded startups

Analysis Details

Generated

May 2, 2026, 09:01 PM UTC

Saved observation

2026-05-02 21:01 UTC

Model Confidence

Medium

Data Snapshot

Price

$0.000129437315170733

Market Cap

$55.7K

24h Volume

$96.5K

Holders

4,124

Liquidity

$49,235.24

Data Sources

On-chain transaction data (buy/sell volumes, transaction counts, unique participants)Holder distribution analytics (concentration, whale activity, retail participation)Trading volume metrics (24h, 4h, 1h volume and price changes)Smart contract analysis (verification status, security score)Token fundamentals (supply, market cap, project description)

Limitations

  • Limited historical data: Token appears to be very new with minimal price history, limiting trend analysis reliability
  • No project metrics: No data on actual pharmaceutical partnerships, user adoption, or real-world implementation
  • No community data: Follower counts, engagement metrics, and community size not provided
  • No audit data: No professional smart contract audit report available for security assessment
  • Incomplete tokenomics: No information on token distribution schedule, vesting, or utility mechanics
  • Market context limited: Insufficient data on how PHAI correlates with broader crypto market or AI sector
  • Speculative environment: Extreme price volatility makes any price prediction highly uncertain

How we keep this honest

Every directional call on these pages is recorded before the outcome is known and scored on our public prediction track record. We apply the same standard to others: our audit of 1,581 crypto YouTube predictions found bullish calls did worse than random timing, and our memecoin pump anatomy study measured what chasing a pump actually costs.

Disclaimer: This analysis is for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation to buy or sell PHAI or any other cryptocurrency. Cryptocurrency investments are highly volatile, speculative, and risky. You can lose 100% of your investment. Past performance does not guarantee future results. Always conduct your own research, understand the risks, and consult with a qualified financial advisor before making any investment decisions. The author of this analysis has no financial interest in PHAI and makes no guarantees about the accuracy or completeness of this analysis. Crypto markets are subject to manipulation, fraud, and regulatory changes that could significantly impact token value. Invest only what you can afford to lose completely.

New reports on Base

All new tokens →

UUSDFUnited States Dividend FundNeutralWworthone life, its worth an attemptNeutralUUSDFUnited States Dividend FundBearishRRSGPCambriaBearishRSGPRSGPCambriaBearishUSDzUSDzUSDzBearishPPLAYERPlayer 8453BearishKKekKekBearish

Questions about PHAI?